Cincinnati-based Cinrx Pharma LLC, a company advancing four early stage candidates for gastrointestinal, cardiovascular and dermatologic indications, has completed a $10 million series B financing backed by both current and new investors. The company, led in part by a roster of former executives of Teva Pharmaceutical Industries Ltd., expects to file investigational new drug applications for all four candidates in the first half of 2018.